Elicit: Clinical Outcomes of Adalimumab in Rheumatoid Arthritis
Clinical Outcomes of Adalimumab in Rheumatoid Arthritis
Adalimumab achieves sustained clinical effectiveness in rheumatoid arthritis
Adalimumab demonstrates consistent clinical effectiveness across diverse rheumatoid arthritis populations, with ACR20 responses of 50-60% at 12 weeks and rapid onset of action, as 71% of ultimate responses occur by week 2. Among patients who persist on therapy, 67-71% achieve low disease activity or remission, with benefits sustained over 10 years of treatment.
Abstract
Adalimumab demonstrates consistent clinical effectiveness across diverse rheumatoid arthritis populations, with ACR20 responses of 50-60% at 12 weeks and rapid onset of action, as 71% of ultimate responses occur by week 2. Among patients who persist on therapy, 67-71% achieve low disease activity or remission, with benefits sustained over 10 years of treatment. Combination therapy with methotrexate substantially outperforms monotherapy, achieving 80% ACR50 responses at 10 years versus 69% with adalimumab alone, and preventing radiographic progression more effectively (modified total Sharp score change of 4.0 versus 8.8 points).
Methods
We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Results
Characteristics of Included Studies
The review included 10 studies evaluating adalimumab in rheumatoid arthritis patients, with study durations ranging from 12 weeks to 10 years.
| Study | Full text retrieved? | Study Type | Patient Population | Disease Duration | Baseline Disease Activity | Treatment Regimen | Duration | Setting |
|---|---|---|---|---|---|---|---|---|
| V. Strand et al., 2012 | Yes | Phase III RCT, double-blind | MTX-naive early RA | Mean 9 months | ≥8 swollen joints, ≥10 tender joints | Adalimumab 40mg EOW ± MTX | 104 weeks | Clinical trial, 133 sites in North America, Europe, Australia |
| B. Haraoui et al., 2011 | Yes | Multicenter, open-label, prospective single cohort | Active RA, 97.8% prior DMARD experience | Mean >12 years | Mean DAS28 6.1 | Adalimumab 40mg EOW + prior DMARDs | 12 weeks | Real-world, 69 sites across Canada |
| S. Bombardieri et al., 2007 | No | Open-label trial | Prior TNF antagonist exposure | Not mentioned | Not mentioned | Adalimumab 40mg EOW | 12 weeks with optional extension | Clinical trial |
| D. Pappas et al., 2017 | Yes | Observational registry | Biologic-naive adults with RA | Mean 7 years | Mean CDAI 19.9 | Not specified | Up to 12 years | Real-world, 170 sites across 40 US states |
| G. Burmester et al., 2014 | Yes | Phase 3b + postmarketing observational (ReAct/ReAlise) | Active RA, failed ≥1 DMARD | Not mentioned | Mean DAS28 6.0 | Adalimumab monotherapy or + DMARDs | Mean 1,016 days (5+ years) | Real-world, 10 European countries and Australia |
| L. B. A. Putte et al., 2003 | No | Phase II RCT, double-blind, placebo-controlled | DMARD-refractory, longstanding active RA | Longstanding | Not mentioned | Adalimumab 20/40/80mg weekly monotherapy | 12 weeks | Clinical trial |
| A. E. van der Bijl et al., 2008 | Yes | Prospective open-label pilot | Active RA, prior infliximab failure | Mean 12 years | DAS28 ≥3.2 | Adalimumab 40mg EOW + existing DMARDs | 16 weeks, maintenance to 56 weeks | Clinical trial |
| E. Keystone et al., 2014 | Yes | RCT with open-label extension (PREMIER OLE) | Early RA, disease duration <3 years | <3 years | DAS28 5.6 ± 1.7 | Initial: adalimumab 40mg EOW ± MTX; OLE: adalimumab with optional MTX | 2 years DB + 8 years OLE | Clinical trial, Australia, Europe, North America |
| D. Karateev et al., 2012 | No | Open-labeled multicenter | Active RA unresponsive to standard therapy | Not mentioned | DAS28-CRP 6.2 ± 0.84 | Adalimumab 40mg EOW + DMARDs | 24 weeks | Clinical trial, Russia |
| D. Furst et al., 2015 | No | Phase 3 open-label extension (DE020) | DMARD-refractory RA | Mean 11.7 years | Not mentioned | Adalimumab 40mg EOW or monthly | Up to 10 years | Clinical trial continuation |
Clinical Effectiveness
Disease Activity and Response Rates
Clinical effectiveness varied by study duration and population characteristics. During short-term studies (12-24 weeks), ACR20 response rates ranged from 37% at 4 weeks to 88% at 24 weeks. At 12 weeks, ACR20 responses were achieved by 50.7-60% of patients, ACR50 by 27-33%, and ACR70 by 8-13%. Long-term studies demonstrated sustained or improved response rates.
Remission and Low Disease Activity
Using DAS28 <2.6 criteria, remission was achieved by 12-15.3% of patients at 12 weeks, increasing to 25% by 24 weeks. At year 10 with adalimumab plus MTX, DAS28 remission was achieved by 75.6%. Low disease activity (DAS28 <3.2) rates were achieved by 28.9% at 12 weeks in the CanACT study, increasing to 92.3% in the PREMIER extension.
Functional Outcomes
Functional status improved across studies, measured primarily by HAQ-DI. In long-term studies, a significant proportion achieved HAQ-DI <0.5, indicating improved functional status.
Radiographic Progression
Radiographic outcomes were assessed in long-term studies. Clinically relevant radiographic progression occurred in only one-third of patients receiving combination therapy, versus over half with monotherapy.
Safety Outcomes
Safety data were reported across varying durations of exposure, from 12 weeks to over 5 years. Overall adverse event rates varied, with serious infections reported at rates of 2.4-2.8 events per 100 patient-years.
Patient-Reported Outcomes and Quality of Life
Health-related quality of life measures showed consistent improvements across studies. Pain assessments demonstrated substantial improvements, with significant reductions in pain scores observed across various studies.
Synthesis
The included studies demonstrate considerable heterogeneity in design, duration, patient populations, and outcomes, yet several consistent patterns emerge regarding adalimumab's efficacy and safety in RA patients.